Executive Editor, Europe Commercial
Latest From Alex Shimmings
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’